Recent Posts
Connect with:
Tuesday / May 24.
HomeminewsNovartis Goes Digital to Tackle Amblyopia

Novartis Goes Digital to Tackle Amblyopia

Novartis plans to accelerate the development of digital technology for the treatment of amblyopia, having acquired the US software start-up Amblyotech.

It is estimated that amblyopia affects roughly 3% of the global population, some of whom could be appropriate candidates for this therapy if approved.1 The condition can lead to poor vision and other quality of life issues if left untreated.2 The condition can impact children and adults beyond their vision, making it difficult to drive and maintain a sense of autonomy. Current treatment options, including patching and/or atropine, are associated with low compliance and low success rates.3 Approved therapies for adults are limited.

In early clinical studies, Amblyotech’s software demonstrated improvements in vision in both children and adults with faster onset compared to standard of care treatments

Designed to enhance compliance, Amblyotech uses active gaming and passive video technology with 3-D glasses, training the eyes to work together to view an image in full. Its software employs a dichoptic display, where each eye is presented with different images using a proprietary algorithm. In early clinical studies, Amblyotech’s software demonstrated improvements in vision in both children and adults with faster onset compared to standard of care treatments.4

“By offering a noninvasive solution that has the potential to be significantly faster than current standards of care such as patching for children and adults impacted by lazy eye, Amblyotech’s software is a great example of how we can reimagine medicine using digital technology,” said Nikos Tripodis, Global Business Franchise Head, Ophthalmology. “We look forward to using our deep clinical development expertise in ophthalmology to accelerate this platform toward regulatory approval, and our global commercial footprint to maximise access for patients who need it.”

Novartis said it will work in partnership with video game developer, Ubisoft, to develop the Amblyotech software as a medical device (SaMD), create a series of engaging games for the device, and conduct a proof of concept study (PoC), planned for later in 2020.



  1. Narinesingh C, Wan W, et al. Amblyopia: A Study Using the McGurk Effect. Investigative Ophthalmology & Visual Science. 2014;55:3158-3164.
  2. National Eye Institute. Amblyopia. https://www.nei.nih.gov/sites/default/files/health-pdfs/FactsAbout_AMBLYOPIA_2015.pdf Accessed November 8, 2019.
  3. Nucci P, Alfarano R, Piantanida A, et al. Compliance in antiamblyopia occlusion therapy. Acta Ophthalmol (Copenh). 1992;70:128-131. doi: 10.1111/j.1755-3768.1992.tb02104.x.
  4. Kelly KR, Jost RM, et al. Binocular iPad Game vs Patching for Treatment of Amblyopia in Children: A Randomized Clinical Trial. JAMA Ophthalmology. 2016;134(12):1402-1408.


By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.